VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 PD-1/IL-2α-Bias Bispecific Fusion Protein Demonstrates Robust Survival Benefits in IO-Resistant NSCLC
2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 PD-1/IL-2α-Bias Bispecific Fusion Protein Demonstrates Robust Survival Benefits in IO-Resistant NSCLC
May 22, 2026 07:49 CST Updated 08:06
Share: